P

    Pharvaris BV (PHVS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $34.61
    -0.71 (-2.01%)

    Market Cap: $2.48B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    43%(10/23)
    Avg Surprise
    -10.77%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.65
    Range$-0.72 - $-0.57
    12 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate Drift
    90d ago$-0.74-13.8%
    60d ago$-0.65+0.2%
    30d ago$-0.65+1.2%
    7d ago$-0.65+0.0%
    Current$-0.65
    Revenue Consensus
    $0
    Range$0 - $0
    9 analysts
    Dec 31, 2026
    EPS Consensus$-0.74
    Range$-0.99 - $-0.34
    13 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    10 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.74---
    Sep 26EST
    		-$-0.65---
    Jun 26
    		$-0.81$-0.74-9.46%Miss+2.4%
    Mar 26
    		$-0.71$-0.62-14.52%Miss+16.5%
    Dec 25
    		$-0.71$-0.62-15.41%Miss-10.9%
    Sep 25
    		$-0.60$-0.67+10.45%Beat+22.1%
    Jun 25
    		$-0.83$-0.77-7.79%Miss-50.9%
    Mar 25
    		$-0.85$-0.83-2.41%Miss-63.5%
    Dec 24
    		$-0.64$-0.73+11.91%Beat+22.0%
    Sep 24
    		$-0.77$-0.60-28.33%Miss-32.8%
    Jun 24
    		$-0.55$-0.58+5.17%Beat+12.7%
    Mar 24
    		$-0.52$-0.57+8.77%Beat+22.4%
    Dec 23
    		$-0.82$-0.58-41.38%Miss+34.4%
    Sep 23
    		$-0.58$-0.59+1.69%Beat-132.0%
    Jun 23
    		$-0.63$-0.58-8.62%Miss-65.8%
    Mar 23
    		$-0.67$-0.76+11.84%Beat-39.6%
    Dec 22
    		$-1.25$-0.70-78.57%Miss-1288.9%
    Sep 22
    		$-0.25N/A+60.32%Beat+35.9%
    Jun 22
    		$-0.38$-0.56+32.14%Beat+59.6%
    Mar 22
    		$-0.48$-0.46-4.35%Miss+27.3%
    Dec 21
    		$-0.09N/A+87.32%Beat+96.6%
    Sep 21
    		$-0.39$-0.47+17.02%Beat+51.2%
    Jun 21
    		$-0.94$-0.46-104.35%Miss-
    Mar 21
    		$-0.66$-0.35-88.57%Miss-
    Dec 20
    		$-2.65$-1.39-90.65%Miss-
    Sep 19
    		$-0.80$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-10.92EV/EBITDA-1.38x
    Price/FCF-13.41xFCF Yield-7.46%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-70.50%ROIC-62.59%
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio11.94xQuick Ratio11.94x
    Trading Statistics
    Beta-2.33Avg Volume649.93K
    52-Week High$38.1352-Week Low$20.65

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$36.35
    SMA 20$35.52
    SMA 50$34.62
    SMA 200$29.32
    EMA 10$35.93
    EMA 20$35.56
    EMA 50$34.37
    EMA 200$29.72

    MACD

    Line: 0.56Signal: 0.68Hist: -0.12

    ADX

    ADX: 25.9+DI: 16.8-DI: 16.6

    Aroon & PSAR

    Aroon Up80.0
    Aroon Down20.0
    PSAR$38.07

    Bollinger Bands

    Upper Band$37.91
    Lower Band$33.13
    %B Position1347%(Upper)
    Band Width0.31

    RSI (14-Day)

    Neutral
    46.3

    Momentum Oscillators

    Stoch %K51.5
    Stoch %D66.0
    Williams %R-68.6
    ROC (10d)-2.0%
    Momentum-0.71
    CCI (20d)-49.1
    MFI (14d)71.8

    Volatility Measures

    ATR (14d)$1.66(4.8%)
    StdDev (20d)1.20
    Hist Vol46.8%(High)

    Volume Flow

    VWAP$34.82
    OBV14.0M
    AD Line4.1M
    CMF (20d)0.038

    Volume Metrics

    Avg Vol (20d)669.7K
    Vol Ratio0.8x
    VWMA (20d)$35.68

    Pivot Points

    R3$38.88
    R2$38.14
    R1$36.73
    Pivot Point$35.99
    S1$34.59
    S2$33.85
    S3$32.44

    Advanced Oscillators

    TSI11.03
    Ultimate Osc44.6
    KST62.21

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total RevenueN/A$0$0$0$0$0$0$0$0$0$0$0
    Cost of Revenue$182,267$106,447N/AN/AN/A$97,024N/AN/A$69,024$71,004N/A$69,908
    Gross Profit$-182,267$-106,447N/AN/AN/A$-97,024N/AN/A$-69,024$-71,004N/A$-69,908
    Operating Expenses$50.79M$44.89M$47.60M$39.66M$40.37M$-42,186,311$45.09M$37.90M$34.38M$28.31M$27.18M$26.20M
    R&D$35.00M$30.66M$34.14M$29.81M$29.61M$30.91M$31.20M$25.78M$23.07M$18.51M$18.61M$18.54M
    SG&A$15.79M$13.46M$13.46M$9.85M$10.77M$11.27M$13.89M$12.12M$11.31M$9.80M$8.57M$7.67M
    Operating Income$-50,788,287$-45,000,039$-47,599,025$-39,664,499$-40,373,097$42.19M$-45,092,034$-37,902,273$-34,382,001$-28,311,859$-27,180,962$-26,201,266
    Interest Income$0$0$0$2.15M$1.00M$1.20M$0$1.98M$2.11M$63,921$0$66,576
    Interest Expense$73,800$87,823$0$0$4.90M$88.22M$0$9,135$2.60M$0$4.82M$0
    Income Before Tax$-47,240,529$-39,567,716$-45,076,932$-37,318,504$-45,277,904$-46,038,156$-33,521,747$-41,480,667$-29,660,450$-27,733,639$-31,999,953$-23,452,323
    Income Tax Expense$602,200$277,597$0$-181,469$202,782$302,667$0$230,091$70,623$285,117$0$146,273
    Net Income$-47,842,729$-39,845,314$-46,740,853$-37,137,035$-45,480,686$-46,340,823$-34,760,940$-41,710,758$-29,731,073$-28,018,756$-32,747,650$-23,598,596
    EBITDA$-50,662,792$-39,373,446N/A$-37,213,352$-45,174,872$-42,081,010N/A$-41,427,960$-29,591,773$-27,667,284N/A$-26,133,333
    EBIT$-50,788,287$-39,479,893N/A$-37,318,504$-45,277,904$-42,186,311N/A$-41,471,532$-29,660,450$-27,733,639N/A$-26,201,266
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about PHVS

    News

    Insider Selling: Pharvaris (NASDAQ:PHVS) CEO Sells 2,292 Shares

    Pharvaris CEO Berndt Modig sold 2,292 shares of the company's stock for $79,692.84, reducing his ownership by 1.72%. Despite this insider selling and the company missing quarterly earnings estimates, analysts maintain a "Moderate Buy" rating with an average price target of $51.08, though recent forecasts suggest larger losses and a slower path to profitability for the clinical-stage biopharmaceutical company. Pharvaris focuses on developing oral therapies for rare bradykinin-driven diseases like hereditary angioedema.

    MarketBeat•8/18/26•
    Somewhat-Bearish

    Pharvaris (PHVS) CEO sells 2,292 shares after RSU vesting

    Pharvaris N.V. (PHVS) CEO Berndt Modig sold 2,292 shares of common stock on August 14, 2026, at an average price of $34.7669 per share. The sale, made pursuant to a Rule 10b5-1 trading plan, occurred after the shares were acquired through the vesting of restricted stock units. Following this transaction, Modig directly holds 130,625 shares and indirectly holds 950,000 shares through Schoodic Management BV.

    Stock Titan•8/18/26•
    Somewhat-Bearish

    Research Analysts Issue Forecasts for Pharvaris Q4 Earnings

    Research analysts at HC Wainwright have issued their Q4 2027 earnings estimates for Pharvaris (NASDAQ:PHVS), projecting a loss of $0.65 per share and maintaining a "Buy" rating. Despite missing previous earnings expectations and recent insider selling of $5.3 million in shares, the company holds an overall "Moderate Buy" consensus rating with an average price target of $51.08. Pharvaris is a clinical-stage biopharmaceutical company focused on developing oral therapies for rare bradykinin-driven diseases like hereditary angioedema.

    MarketBeat•8/17/26•
    Somewhat-Bullish

    PHVS (NASDAQ: PHVS) holder Berndt Modig plans 2,292-share stock sale

    Berndt Modig plans to sell 2,292 shares of Pharvaris N.V. (NASDAQ: PHVS) common stock, valued at approximately $78,019.68, through Morgan Stanley Smith Barney LLC. These shares are related to Restricted Stock Units dated August 11, 2026. The filing also discloses previous 10b5-1 sales by Modig over the past three months, including sales on July 13, 2026, June 15, 2026, and May 15, 2026.

    Stock Titan•8/15/26•
    Neutral

    General Atlantic group (PHVS) discloses 5.36M Pharvaris shares, 7.6% ownership

    General Atlantic entities have disclosed a beneficial ownership of 5,359,727 ordinary shares in Pharvaris N.V. (PHVS), representing a 7.6% stake in the company. This disclosure was made via a Schedule 13G/A filing, with General Atlantic PH B.V. identified as the sole record holder. The ownership percentage is based on 70,204,506 outstanding ordinary shares of Pharvaris as of June 30, 2026.

    Stock Titan•8/15/26•
    Neutral

    Frequently Asked Questions About PHVS

    Does PHVS pay dividends?
    Pharvaris BV (PHVS) does not currently pay a regular dividend.
    What is PHVS's market cap?
    Pharvaris BV (PHVS) has a market capitalization of $2.48B with a current stock price of $34.61.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In